High Tide Reports Record Q2 2026 Revenue, EBITDA, and First Positive Net Income

summarizeSummary

High Tide Inc. announced record Q2 2026 financial results, including $179.3 million in revenue and $13.9 million in Adjusted EBITDA, alongside achieving positive net income for the first time.

check_boxKey Events

• Record Financial Performance

  Reported record Q2 2026 revenue of $179.3 million (+30% YoY) and record Adjusted EBITDA of $13.9 million (+73% YoY), marking the fastest growth rates in 11 and 9 quarters, respectively.

• Achieved Positive Net Income

  The company generated positive net income of $0.024 million, a significant improvement from a net loss of $2.8 million in the prior year and $0.4 million sequentially.

• Strong German Medical Cannabis Growth

  Its German subsidiary, Remexian Pharma GmbH, achieved record revenue of $31.6 million and distributed a record 7.6 tonnes of medical cannabis, increasing its market share to over 14%.

• Secured Non-Dilutive Financing

  Received final credit approval for C$40 million in new senior secured credit facilities from Bank of Montreal, replacing existing facilities and supporting future growth.

auto_awesomeAnalysis

High Tide Inc. delivered exceptionally strong second-quarter results, marking a significant financial turnaround with record revenue, Adjusted EBITDA, and, notably, its first positive net income. This performance is driven by robust growth in its Canadian retail operations and a substantial increase in its German medical cannabis distribution segment. The company also secured C$40 million in new senior secured credit facilities, providing non-dilutive capital for future expansion. These results indicate strong operational execution and a positive trajectory for the company's profitability and growth ambitions.